| Preface |
|
|
|
|
2 | (28) |
|
|
|
2 | (1) |
|
|
|
2 | (1) |
|
|
|
3 | (10) |
|
|
|
3 | (5) |
|
|
|
8 | (2) |
|
|
|
10 | (2) |
|
|
|
12 | (1) |
|
Origin of the AIDS Epidemic |
|
|
13 | (8) |
|
|
|
14 | (2) |
|
|
|
16 | (2) |
|
|
|
18 | (1) |
|
Entry into the United States |
|
|
19 | (2) |
|
The First Decades and Beyond |
|
|
21 | (4) |
|
|
|
21 | (3) |
|
AIDS in the Twenty-First Century |
|
|
24 | (1) |
|
|
|
25 | (5) |
|
|
|
30 | (28) |
|
|
|
30 | (1) |
|
|
|
30 | (1) |
|
Structure of Viruses and HIV |
|
|
31 | (5) |
|
Replication of Viruses and HIV |
|
|
36 | (12) |
|
|
|
37 | (3) |
|
Penetration and Infection |
|
|
40 | (2) |
|
|
|
42 | (2) |
|
HIV Activation and Release |
|
|
44 | (1) |
|
|
|
45 | (3) |
|
|
|
48 | (3) |
|
|
|
48 | (2) |
|
|
|
50 | (1) |
|
|
|
51 | (2) |
|
|
|
53 | (5) |
|
The Immune System and HIV |
|
|
58 | (26) |
|
|
|
58 | (1) |
|
|
|
58 | (2) |
|
Development of the Immune System |
|
|
60 | (4) |
|
|
|
64 | (1) |
|
|
|
65 | (6) |
|
|
|
65 | (3) |
|
Antibody-Mediated Immunity |
|
|
68 | (3) |
|
HIV and the Immune System |
|
|
71 | (9) |
|
|
|
74 | (3) |
|
|
|
77 | (3) |
|
|
|
80 | (4) |
|
Defining and Recognizing AIDS |
|
|
84 | (30) |
|
|
|
84 | (1) |
|
|
|
84 | (1) |
|
|
|
85 | (1) |
|
|
|
86 | (4) |
|
|
|
90 | (4) |
|
Acquired Immune Deficiency Syndrome |
|
|
94 | (14) |
|
The CDC Stages of Disease |
|
|
95 | (2) |
|
The Walter Reed Classification System |
|
|
97 | (1) |
|
|
|
98 | (1) |
|
|
|
98 | (2) |
|
|
|
100 | (3) |
|
|
|
103 | (5) |
|
|
|
108 | (3) |
|
|
|
111 | (3) |
|
|
|
114 | (38) |
|
|
|
114 | (1) |
|
|
|
114 | (1) |
|
AIDS and the Epidemiologist |
|
|
115 | (2) |
|
|
|
117 | (25) |
|
|
|
120 | (1) |
|
|
|
121 | (3) |
|
AIDS in Injection Drug Users |
|
|
124 | (1) |
|
|
|
125 | (3) |
|
|
|
128 | (2) |
|
|
|
130 | (5) |
|
|
|
135 | (3) |
|
|
|
138 | (3) |
|
Other Transmission Methods |
|
|
141 | (1) |
|
How AIDS Is Not Transmitted |
|
|
142 | (2) |
|
|
|
142 | (2) |
|
|
|
144 | (1) |
|
AIDS in Schools and Colleges |
|
|
144 | (3) |
|
|
|
147 | (5) |
|
Preventing HIV Transmission |
|
|
152 | (32) |
|
|
|
152 | (1) |
|
|
|
152 | (1) |
|
|
|
153 | (9) |
|
|
|
155 | (4) |
|
|
|
159 | (3) |
|
Protecting Health Care Workers |
|
|
162 | (10) |
|
|
|
163 | (1) |
|
|
|
164 | (1) |
|
|
|
165 | (1) |
|
|
|
166 | (1) |
|
|
|
167 | (1) |
|
Decontamination Procedures |
|
|
168 | (1) |
|
|
|
169 | (3) |
|
Protecting Public Safety Workers |
|
|
172 | (5) |
|
Fire and Emergency Medical Services |
|
|
173 | (2) |
|
|
|
175 | (2) |
|
AIDS Education in the Schools |
|
|
177 | (2) |
|
|
|
179 | (5) |
|
HIV Testing and Diagnosis |
|
|
184 | (28) |
|
|
|
184 | (1) |
|
|
|
184 | (1) |
|
|
|
185 | (10) |
|
Enzyme-Linked Immunosorbent Assay (ELISA) |
|
|
186 | (2) |
|
|
|
188 | (3) |
|
False Positives and Negatives |
|
|
191 | (2) |
|
|
|
193 | (1) |
|
Home and Simplified Tests |
|
|
194 | (1) |
|
HIV Antigen (Viral Load) Tests |
|
|
195 | (7) |
|
|
|
196 | (1) |
|
The Polymerase Chain Reaction |
|
|
197 | (3) |
|
Advantages of the Viral Load Test |
|
|
200 | (2) |
|
Protein and T-Lymphocyte Tests |
|
|
202 | (1) |
|
Implications of HIV Testing |
|
|
202 | (5) |
|
|
|
204 | (1) |
|
|
|
205 | (2) |
|
|
|
207 | (5) |
|
Treating HIV Infection and AIDS |
|
|
212 | (48) |
|
|
|
212 | (1) |
|
|
|
213 | (1) |
|
General Principles of AIDS Treatment |
|
|
214 | (6) |
|
Objectives of Therapeutic Drugs |
|
|
214 | (2) |
|
Approaches to Drug Therapy |
|
|
216 | (2) |
|
Mutations and Other Considerations |
|
|
218 | (2) |
|
Reverse Transcriptase Inhibitors |
|
|
220 | (10) |
|
|
|
223 | (4) |
|
|
|
227 | (2) |
|
|
|
229 | (1) |
|
|
|
230 | (15) |
|
|
|
230 | (3) |
|
|
|
233 | (4) |
|
|
|
237 | (1) |
|
|
|
238 | (1) |
|
|
|
239 | (1) |
|
Miscellaneous Therapeutic Agents |
|
|
240 | (3) |
|
|
|
243 | (2) |
|
Treating Opportunistic Diseases |
|
|
245 | (2) |
|
|
|
245 | (1) |
|
|
|
246 | (1) |
|
Drug Development and Testing |
|
|
247 | (4) |
|
|
|
248 | (3) |
|
Key Questions about Drug Testing |
|
|
251 | (1) |
|
|
|
251 | (4) |
|
|
|
252 | (1) |
|
|
|
253 | (1) |
|
|
|
254 | (1) |
|
|
|
255 | (5) |
|
|
|
260 | (28) |
|
|
|
260 | (1) |
|
|
|
260 | (2) |
|
General Vaccine Strategies |
|
|
262 | (3) |
|
|
|
263 | (2) |
|
|
|
265 | (7) |
|
Sterilizing and Therapeutic Vaccines |
|
|
266 | (1) |
|
|
|
267 | (4) |
|
|
|
271 | (1) |
|
|
|
272 | (3) |
|
|
|
274 | (1) |
|
Problems in Vaccine Development |
|
|
275 | (2) |
|
|
|
275 | (1) |
|
|
|
276 | (1) |
|
|
|
277 | (2) |
|
|
|
279 | (4) |
|
|
|
280 | (2) |
|
|
|
282 | (1) |
|
|
|
283 | (5) |
|
|
|
288 | (28) |
|
|
|
288 | (1) |
|
|
|
288 | (1) |
|
|
|
289 | (16) |
|
|
|
292 | (3) |
|
|
|
295 | (3) |
|
|
|
298 | (5) |
|
AIDS and Medical Professionals |
|
|
303 | (2) |
|
Caring for the AIDS Patient |
|
|
305 | (2) |
|
Education and Terminology |
|
|
306 | (1) |
|
|
|
306 | (1) |
|
|
|
307 | (4) |
|
|
|
308 | (2) |
|
|
|
310 | (1) |
|
|
|
311 | (5) |
| Appendix A Answers to Review Questions |
|
316 | (1) |
| Appendix B A Suggested Format for a 10-Session Course: The Biological Basis of AIDS |
|
317 | (2) |
| Pronunciation Guide |
|
319 | (2) |
| Glossary |
|
321 | (7) |
| Index |
|
328 | |
Shopping Cart
